ViaLase, Inc., an Aliso Viejo, CA-based clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, closed approx. $40m in Series C financing.
The round was led by a new investor along with support from current investors including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision, an ophthalmology investment platform supported by KKR.
Led by Tibor Juhasz, PhD, Founder and Chief Executive Officer, the company intends to use the funds to ensure the continued advancement of clinical, regulatory, and commercial milestones of its ViaLase® Laser*. If approved, the ViaLase Laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma (POAG).
The ViaLase Laser combines femtosecond laser technology and micron-level image guidance to deliver a noninvasive glaucoma treatment called femtosecond laser image-guided high-precision trabeculotomy, or FLigHT. The novel FLigHT procedure will provide physicians with precision and visibility when creating channels in the trabecular meshwork (TM) to lower intraocular pressure (IOP) through a noninvasive, nonsurgical approach.
*The ViaLase Laser is an investigational device and is not approved for commercial use.
FinSMEs
01/04/2024